Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

72.99 USD -2.57 (-3.40%)
Official Closing Price Updated: 7:59 PM EST, Jan 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Axsome Thera

< Previous 1 2 3 4 5 6 Next >
Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation
From GlobeNewswire News Releases
Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine
From GlobeNewswire News Releases
Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation
From GlobeNewswire News Releases
Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression
From GlobeNewswire News Releases
Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder
From GlobeNewswire News Releases
On the Trail of Better Therapeutics for Depression
From InvestorBrandNetwork
On the Trail of Better Therapeutics for Depression
NetworkNewsWire Editorial Coverage 
From PR Newswire
Axsome Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Electrotherapy: Medical Company Medical Company Leaders MedTronic PLC (NYSE: MDT), Electromedical Technologies, Inc. (OTCQB: EMED) And Abbott Laboratories (NYSE: ABT) Offer Solutions for Chronic Pain
Tags Google News IPS English
From iCrowdNewswire
Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization™ Platform
From GlobeNewswire News Releases
Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization™ Platform
Axsome and Veeva announced a strategic partnership to augment the build of Axsome’s Digital-Centric Commercialization (DCC™) platform. 
From Business Wire News Releases
Axsome Therapeutics to Present Data from the ADVANCE-1 Trial of AXS-05 in Alzheimer’s Disease Agitation at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From GlobeNewswire News Releases
Axsome Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020
From GlobeNewswire News Releases
Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules Capital
From GlobeNewswire News Releases
Axsome Therapeutics Presents New Data from MOMENTUM Phase 3 Trial with AXS-07 Demonstrating Rapid Onset of Action and Reduced Symptom Recurrence in the Acute Treatment of Migraine
From GlobeNewswire News Releases
Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting
From GlobeNewswire News Releases
Axsome Therapeutics Announces AXS-07 Phase 3 Migraine Trial Results Selected by the American Academy of Neurology Science Committee as Featured Presentation
From GlobeNewswire News Releases
Axsome Therapeutics Presents New Data from GEMINI Phase 3 Trial with AXS-05 Demonstrating Rapid and Significant Improvements in Patient-Reported Outcomes in Major Depressive Disorder
From GlobeNewswire News Releases
Axsome Therapeutics to Present New Data for AXS-05 in Major Depressive Disorder at the 33rd European College of Neuropsychopharmacology Congress
From GlobeNewswire News Releases
Axsome Therapeutics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
From GlobeNewswire News Releases
Axsome Therapeutics to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Axsome Therapeutics Confirms Pivotal Status and Advancement of AXS-05 for the Treatment of Alzheimer’s Disease Agitation Based on Successful FDA Breakthrough Therapy Meeting
From GlobeNewswire News Releases
Axsome Therapeutics to Present Data from the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy at the SLEEP 2020 Annual Meeting
From GlobeNewswire News Releases
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-07 for the Acute Treatment of Migraine
From GlobeNewswire News Releases
Axsome Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Axsome Therapeutics Announces Further Progress in AXS-05 Depression Clinical Program
From GlobeNewswire News Releases
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy
From GlobeNewswire News Releases
Axsome Therapeutics to Report Second Quarter 2020 Financial Results on August 10, 2020
From GlobeNewswire News Releases
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-05 for the Treatment of Major Depressive Disorder
From GlobeNewswire News Releases
Thinking about trading options or stock in Axsome Therapeutics, Virgin Galactic, Dynavax Technologies, Big Lots, or Walt Disney?
InvestorsObserver issues critical PriceWatch Alerts for AXSM, SPCE, DVAX, BIG, and DIS. 
From PR Newswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.